Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It is a nucleotide-sensing TLR that is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion, and the inflammatory response. The Toll Like Receptor 3 (CD283 or TLR3) Development market research report provides an in-depth analysis of Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects.

Mechanisms of Action of Toll Like Receptor 3 Pipeline Market

The mechanisms of action of the Toll Like Receptor 3 pipeline market are Toll Like Receptor 3 Agonist, Toll Like Receptor 3 Antagonist, and Toll Like Receptor 3 Activator.

Toll Like Receptor 3 pipeline market, by mechanisms of action

Toll Like Receptor 3 pipeline market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Toll Like Receptor 3 Pipeline Market

The routes of administration in the Toll Like Receptor 3 pipeline market are intratumor, nasal, intraperitoneal, intravenous, intradermal, intramuscular, subcutaneous, and intravesical.

Toll Like Receptor 3 pipeline market, by routes of administration

Toll Like Receptor 3 pipeline market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Toll Like Receptor 3 Pipeline Market

The molecule types in the Toll Like Receptor 3 pipeline market are oligonucleotide, small molecule, antibody, gene therapy, peptide, and vaccine.

Toll Like Receptor 3 pipeline market, by molecule types

Toll Like Receptor 3 pipeline market, by molecule types

For more molecule type insights, download a free report sample

Key Toll Like Receptor 3 Pipeline Market Companies

Some of the key companies in the Toll Like Receptor 3 pipeline market are 13therapeutics Inc, AIM ImmunoTech Inc, 4 Aston Sci Co Ltd, Glysantis Inc, HDT Bio Corp, Highlight Therapeutics SL, Oncovir Inc, PrEP Biopharm Ltd, Tollys SAS, Wyvern Pharmaceuticals Inc, and Yisheng Biopharma Co Ltd.

Toll Like Receptor 3 pipeline market, by companies

Toll Like Receptor 3 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Mechanisms of Action Toll Like Receptor 3 Agonist, Toll Like Receptor 3 Antagonist, and Toll Like Receptor 3 Activator
Routes of Administration Intratumor, Nasal, Intraperitoneal, Intravenous, Intradermal, Intramuscular, Subcutaneous, and Intravesical
Molecule Types Oligonucleotide, Small Molecule, Antibody, Gene Therapy, Peptide, and Vaccine
Key Companies 13therapeutics Inc, AIM ImmunoTech Inc, 4 Aston Sci Co Ltd, Glysantis Inc, HDT Bio Corp, Highlight Therapeutics SL, Oncovir Inc, PrEP Biopharm Ltd, Tollys SAS, Wyvern Pharmaceuticals Inc, and Yisheng Biopharma Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Toll Like Receptor 3 (CD283 or TLR3).
  • Reviews of Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Toll Like Receptor 3 (CD283 or TLR3) therapeutics and enlists all their major and minor projects.
  • Assessment of Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Toll Like Receptor 3 (CD283 or TLR3).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3).
  • Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

13therapeutics Inc
AIM ImmunoTech Inc
Aston Sci Co Ltd
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Tollys SAS
Wyvern Pharmaceuticals Inc
Yisheng Biopharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toll Like Receptor 3 (CD283 or TLR3) – Overview

Toll Like Receptor 3 (CD283 or TLR3) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Toll Like Receptor 3 (CD283 or TLR3) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 3 (CD283 or TLR3) – Companies Involved in Therapeutics Development

13therapeutics Inc

AIM ImmunoTech Inc

Aston Sci Co Ltd

Glysantis Inc

HDT Bio Corp

Highlight Therapeutics SL

Oncovir Inc

PrEP Biopharm Ltd

Tollys SAS

Wyvern Pharmaceuticals Inc

Yisheng Biopharma Co Ltd

Toll Like Receptor 3 (CD283 or TLR3) – Drug Profiles

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases – Drug Profile

Product Description

Mechanism Of Action

AST-065 – Drug Profile

Product Description

Mechanism Of Action

BO-112 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GLY-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HDT-401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

P-7 – Drug Profile

Product Description

Mechanism Of Action

Poly-ICLC – Drug Profile

Product Description

Mechanism Of Action

History of Events

PrEP-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

rintatolimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome – Drug Profile

Product Description

Mechanism Of Action

TL-532 – Drug Profile

Product Description

Mechanism Of Action

History of Events

WYV-ONC – Drug Profile

Product Description

Mechanism Of Action

YSHBV-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Toll Like Receptor 3 (CD283 or TLR3) – Dormant Products

Toll Like Receptor 3 (CD283 or TLR3) – Discontinued Products

Toll Like Receptor 3 (CD283 or TLR3) – Product Development Milestones

Featured News & Press Releases

Mar 09, 2022: AIM ImmunoTech announces abstract from university of Pittsburgh medical center accepted for presentation at the AACR 2022 annual meeting

Mar 09, 2022: AIM ImmunoTech announces abstracts from Roswell Park Comprehensive Cancer Center accepted for presentation in a late-breaking poster session at the AACR 2022 annual meeting

Mar 08, 2022: AIM ImmunoTech announces publication of positive data from late-stage pancreatic cancer Early Access Program (EAP) in the cancers special issue: combination and innovative therapies for Pancreatic Cancer

Jan 24, 2022: AIM ImmunoTech announces publication of positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer

Dec 09, 2021: AIM ImmunoTech’s Ampligen safety data presented at Eighth European Scientific Working Group on Influenza

Dec 02, 2021: Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of Cancer

Nov 12, 2021: Positive phase 2b results in 2nd line melanoma

Oct 19, 2021: AIM ImmunoTech submits IND and accompanying fast track application for phase 2 trial of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer

Oct 06, 2021: AIM ImmunoTech publishes phase 1 clinical study data supporting the safety of Ampligen as an intranasal therapy

Oct 04, 2021: AIM ImmunoTech provides clinical updates on planned phase 2 study of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer

Sep 29, 2021: AIM seeks FDA approval to conduct Phase II Covid-19 therapy trials

Sep 27, 2021: AIM ImmunoTech files provisional patent application for Ampligen as an early-onset intranasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses

Sep 21, 2021: AIM ImmunoTech announces positive progress on requested FDA meeting for proposed Ampligen clinical trial in post-COVID-19 cognitive dysfunction

Sep 20, 2021: AIM ImmunoTech provides an update on its pending phase 2a human challenge trial using its drug Ampligen

Sep 09, 2021: AIM seeks FDA approval for Phase II trial of Ampligen for Covid-19

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by 13therapeutics Inc, 2022

Pipeline by AIM ImmunoTech Inc, 2022

Pipeline by Aston Sci Co Ltd, 2022

Pipeline by Glysantis Inc, 2022

Pipeline by HDT Bio Corp, 2022

Pipeline by Highlight Therapeutics SL, 2022

Pipeline by Oncovir Inc, 2022

Pipeline by PrEP Biopharm Ltd, 2022

Pipeline by Tollys SAS, 2022

Pipeline by Wyvern Pharmaceuticals Inc, 2022

Pipeline by Yisheng Biopharma Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Toll Like Receptor 3 (CD283 or TLR3) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.